• 1
    Loar AS. Canine thyroid tumors. In: Kirk RW, ed. Current Veterinary Therapy. Philadelphia, PA: WB Saunders Co; 1986:10331039.
  • 2
    Wucherer KL, Wilke V. Thyroid cancer in dogs: An update based on 638 cases (1995-2005). J Am Anim Hosp Assoc 2010;46:249254.
  • 3
    Carver JR, Kapatkin A, Patnaik AK. A comparison of medullary thyroid carcinoma and thyroid adenocarcinoma in dogs: A retrospective study of 38 cases. Vet Surg 1995;24:315319.
  • 4
    Harari J, Patterson JS, Rosenthal RC. Clinical and pathologic features of thyroid tumors in 26 dogs. J Am Vet Med Assoc 1986;188:11601164.
  • 5
    Soh EY, Duh QY, Sobhi SA, et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 1997;82:37413747.
  • 6
    Keefe SM, Cohen MA, Brose MS. Targeting vascular endothelial growth factor receptor in thyroid cancer: The intracellular and extracellular implications. Clin Cancer Res 2010;16:778783.
  • 7
    Spitzweg C. Gene therapy in thyroid cancer. Horm Metab Res 2009;41:500509.
  • 8
    Zacchetti A, van Garderen E, Rutteman GR. Immunohistochemical evaluation of p53 expression with different antibodies in malignant canine tumours with or without p53 gene mutation. Vet Comp Oncol 2007;5:108118.
  • 9
    Donghi R, Longoni A, Pilotti S, et al. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 1993;91:17531760.
  • 10
    Devilee P, Van Leeuwen IS, Voesten A, et al. The canine p53 gene is subject to somatic mutations in thyroid carcinoma. Anticancer Res 1994;14:20392046.
  • 11
    Spugnini EP, Porrello A, Citro G, et al. COX-2 overexpression in canine tumors: Potential therapeutic targets in oncology. Histol Histopathol 2005;20:13091312.
  • 12
    Knapp DW, Richardson RC, Chan TC, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273278.
  • 13
    Yaqub S, Henjum K, Mahic M, et al. Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol Immunother 2008;57:813821.
  • 14
    Nadeau ME, Kitchell BE. Evaluation of the use of chemotherapy and other prognostic variables for surgically excised canine thyroid carcinoma with and without metastasis. Can Vet J 2011;52:994998.
  • 15
    Fineman LS, Hamilton TA, de Gortari A, et al. Cisplatin chemotherapy for treatment of thyroid carcinoma in dogs: 13 cases. J Am Anim Hosp Assoc 1998;34:109112.
  • 16
    Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002;2:4858.
  • 17
    Zandvliet M, Teske E, Chapuis T, et al. Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein. J Vet Pharmacol Ther 2013;36:583587.
  • 18
    Zatelli MC, Luchin A, Piccin D, et al. Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J Clin Endocrinol Metab 2005;90:57545760.
  • 19
    Ginn PE. Immunohistochemical detection of P-glycoprotein in formalin-fixed and paraffin-embedded normal and neoplastic canine tissues. Vet Pathol 1996;33:533541.
  • 20
    Kiupel M, Capen C, Miller M, et al. Histological classification of the endocrine system of domestic animals. In: Schulman FY, ed. WHO International Histological Classification of Tumors of Domestic Animals. Washington, DC: Armed Forces Institute of Pathology; 2008:2539.
  • 21
    Patnaik AK, Lieberman PH. Gross, histologic, cytochemical, and immunocytochemical study of medullary thyroid carcinoma in sixteen dogs. Vet Pathol 1991;28:223233.
  • 22
    Santos AA, Oliveira JT, Lopes CC, et al. Immunohistochemical expression of vascular endothelial growth factor in canine mammary tumours. J Comp Pathol 2010;143:268275.
  • 23
    Kim YW, Do IG, Park YK. Expression of the GLUT1 glucose transporter, p63 and p53 in thyroid carcinomas. Pathol Res Pract 2006;202:759765.
  • 24
    Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000;89:26372645.
  • 25
    Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations. Cancer Res 1996;56:30103020.
  • 26
    Axiotis CA, Monteagudo C, Merino MJ, et al. Immunohistochemical detection of P-glycoprotein in endometrial adenocarcinoma. Am J Pathol 1991;138:799806.
  • 27
    London C, Mathie T, Stingle N, et al. Preliminary evidence for biologic activity of toceranib phosphate (Palladia(R)) in solid tumours. Vet Comp Oncol 2012;10:194205.
  • 28
    Popovtzer A, Morgenstein S, Roizman P, et al. Cyclooxygenase-2 expression in medullary thyroid carcinoma. Head Neck 2007;29:559563.
  • 29
    Mohammed SI, Bennett PF, Craig BA, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002;62:356358.
  • 30
    Massart C, Gibassier J, Lucas C, et al. Expression of the MDR1 gene in five human cell lines of medullary thyroid cancer and reversion of the resistance to doxorubicine by ciclosporin A and verapamil. Bull Cancer 1996;83:3945.
  • 31
    Schlumberger M, Abdelmoumene N, Delisle MJ, et al. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br J Cancer 1995;71:363365.
  • 32
    Patel VA, Dunn MJ, Sorokin A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem 2002;277:3891538920.
  • 33
    Rahman M, Selvarajan K, Hasan MR, et al. Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo. Neoplasia 2012;14:624633.